Latest filing published 28 Nov 2022 for Enzo Biochem INC, €191k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Hamid Erfanian: trading record in brief
Hamid Erfanian (chief executive) discloses dealings in Enzo Biochem Inc to SEC (Form 4). We count 4 filings; the first trade dates from 8 November 2021 and the latest from 23 November 2022.
Every open-market trade on record is a purchase: 2 purchases worth €201k, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 2 share grants. In 2022 alone, the filings show 2 purchases and no sales.
Most recently, on 28 November 2022, the filings show an open-market purchase worth €191k in Enzo Biochem Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Hamid Erfanian
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 100,000 shares@ US$1.9784.1% of flowCommon Stock, $0.01 Par ValueSEC:0001213900-22-075598:0Canonical exit: 21 Feb 2023 (T+90)
- 4,600 shares@ US$2.194.2% of flowCommon Stock, $0.01 Par ValueSEC:0001213900-22-033623:0Canonical exit: 13 Sept 2022 (T+90)
- 10,000 shares@ US$2.9011.7% of flowCommon Stock, $0.01 Par ValueSEC:0001213900-22-019771:0
- 260,000 shares0Common Stock, $0.01 Par ValueSEC:0001213900-21-058202:0
4 of 4 declarations
